BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 16019486)

  • 1. Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses.
    Mundhada S; Shaw J; Mori S; Savary CA; Mullen CA
    Leuk Lymphoma; 2005 Apr; 46(4):571-80. PubMed ID: 16019486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
    Anderson LD; Petropoulos D; Everse LA; Mullen CA
    Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease.
    Anderson LD; Savary CA; Mullen CA
    Blood; 2000 Apr; 95(7):2426-33. PubMed ID: 10733517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation.
    Teshima T; Mach N; Hill GR; Pan L; Gillessen S; Dranoff G; Ferrara JL
    Cancer Res; 2001 Jan; 61(1):162-71. PubMed ID: 11196155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconstructing immunity after allogeneic transplantation.
    Giver CR; Li JM; Hossain MS; Lonial S; Waller EK
    Immunol Res; 2004; 29(1-3):269-82. PubMed ID: 15181288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation.
    Mori S; El-Baki H; Mullen CA
    Bone Marrow Transplant; 2003 May; 31(10):865-75. PubMed ID: 12748663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR; Majewski D
    Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of tumor vaccines on graft versus tumor activity and graft versus host disease in allogeneic bone marrow transplantation.
    Mullen CA
    Leuk Lymphoma; 2002 Mar; 43(3):503-10. PubMed ID: 12002752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation.
    Ash S; Stein J; Askenasy N; Yaniv I
    Br J Cancer; 2010 Nov; 103(10):1597-605. PubMed ID: 20978501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
    Marks L; Altman NH; Podack ER; Levy RB
    Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft versus neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD.
    Ash S; Gigi V; Askenasy N; Fabian I; Stein J; Yaniv I
    Cancer Immunol Immunother; 2009 Dec; 58(12):2073-84. PubMed ID: 19437016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
    Ito M; Shizuru JA
    Biol Blood Marrow Transplant; 1999; 5(6):357-68. PubMed ID: 10595813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
    Waller EK; Boyer M
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
    Zilberberg J; Feinman R; Korngold R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.